Migraine (Acute) | Treatment Algorithms | Claims Data Analysis | US | 2022

Triptans have long been the mainstay of acute treatment of migraine; however, in 2020, three novel oral nontriptan brands—Eli Lilly’s Reyvow, AbbVie / Allergan’s Ubrelvy, and Biohaven’s Nurtec ODT—entered the U.S. market. These therapies offer clinically distinct alternatives to triptans, particularly for patients who cannot tolerate, are contraindicated to, or do not adequately respond to triptans. Additional oral nontriptans are set to enter the market in the coming years and will offer further choice. In this report, we leverage national patient-level claims data to assess the uptake and performance of newer brands versus those of the standard of care. Understanding the treatment paradigms and patient flow will provide needed context for developers entering a heavily generic and increasingly saturated market.

QUESTIONS ANSWERED

• What patient shares do key acute therapies garner by line of therapy in newly diagnosed migraine patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed migraine patients?
• What is the dynamic between Reyvow, Ubrelvy, and Nurtec ODT? How have they been integrated into practice, and what are their sources of business?
• What percentage of migraine patients began acute drug therapy during our two-year prescription-tracking period? What percentage of patients progress to later lines of therapy, and how quickly do they progress?
• What percentage of migraine patients are treated with monotherapy versus combination therapy for acute attacks? What are the most commonly used combinations?
• What are the product-level compliance and persistency rates among drug-treated migraine patients?

PRODUCT DESCRIPTION

Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.

Markets covered: United States

Key companies: Eli Lilly, AbbVie / Allergan, Biohaven Pharmaceuticals, Upsher-Smith, Currax Pharmaceuticals

Key drugs: Reyvow, Ubrelvy, Nurtec ODT, Onzetra Xsail, Tosymra, Zembrace SymTouch, generic triptans, ergot derivatives, Cambia

SOLUTION ENHANCEMENT

The accompanying interactive dashboard provides novel delivery of data with interactive visuals, easier navigation, and expanded analyses.